| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2124450 | European Journal of Cancer | 2008 | 8 Pages |
Abstract
Daily therapy with RAD001 plus letrozole is promising: the results suggest anti-tumour activity with no PK interactions. The overall safety profile of the combination is consistent with that expected for RAD001 monotherapy. A daily dose of RAD001 10Â mg is recommended for further trials.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Ahmad Awada, Fatima Cardoso, Christel Fontaine, Luc Dirix, Jacques De Grève, Christos Sotiriou, Jutta Steinseifer, Carine Wouters, Chiaki Tanaka, Ulrike Zoellner, Pui Tang, Martine Piccart,